Edition:
India

AveXis Inc (AVXS.OQ)

AVXS.OQ on NASDAQ Stock Exchange Global Select Market

104.87USD
2:29am IST
Change (% chg)

$-0.14 (-0.13%)
Prev Close
$105.01
Open
$103.21
Day's High
$105.46
Day's Low
$102.55
Volume
1,017,424
Avg. Vol
154,984
52-wk High
$119.00
52-wk Low
$50.59

Chart for

About

AveXis, Inc. is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company's product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for... (more)

Overall

Beta: --
Market Cap(Mil.): $3,310.99
Shares Outstanding(Mil.): 31.93
Dividend: --
Yield (%): --

Financials

BRIEF-Avexis Announces Expanded Clinical Development Program For AVXS-101 In Spinal Muscular Atrophy

* AVEXIS ANNOUNCES EXPANDED CLINICAL DEVELOPMENT PROGRAM FOR AVXS-101 IN SPINAL MUSCULAR ATROPHY

16 Jan 2018

BRIEF-Regenxbio And Avexis Announce Expansion Of Relationship For Spinal Muscular Atrophy treatments

* REGENXBIO AND AVEXIS ANNOUNCE EXPANSION OF RELATIONSHIP THROUGH AMENDED LICENSE AGREEMENT FOR THE DEVELOPMENT AND COMMERCIALIZATION OF TREATMENTS FOR SPINAL MUSCULAR ATROPHY

08 Jan 2018

BRIEF-Avexis Inc Plans To Request A Pre-BLA Meeting For AVXS-101 In Q2 ​

* AVEXIS ANNOUNCES ALIGNMENT WITH FDA ON NEXT STEPS TOWARD A BLA SUBMISSION FOR AVXS-101 IN SMA TYPE 1

05 Jan 2018

BRIEF-Avexis plans to initiate Phase 1 trial in SMA Type 2

* AVEXIS ANNOUNCES PLAN TO INITIATE PHASE 1 TRIAL IN SMA TYPE 2 UTILIZING INTRATHECAL DELIVERY OF AVXS-101 Source text for Eikon: Further company coverage:

14 Dec 2017

BRIEF-Avexis posts Q3 loss per share $1.52

* Avexis reports third quarter 2017 financial and operating results

10 Nov 2017

BRIEF-Avexis Inc CFO Thomas Dee resigns

* Avexis Inc - ‍on October 14 Thomas J. Dee resigned as senior vice president, chief financial officer - SEC filing

20 Oct 2017

BRIEF-AveXis to report top-line data from phase 1 clinical trial of AVXS-101

* AveXis to report top-line data from the Phase 1 clinical trial of AVXS-101 in SMA Type 1 at the International Annual Congress Of The World Muscle Society

03 Oct 2017

BRIEF-Avexis to initiate pivotal trial of AVXS-101 in SMA type 1

* Avexis announces plan to initiate pivotal trial of AVXS-101 in SMA type 1 using product from new GMP commercial process

29 Sep 2017

BRIEF-AveXis reports Q2 loss per share $2.07

* AveXis reports second quarter 2017 financial and operating results

11 Aug 2017

Earnings vs. Estimates